Zai Lab Limited

NASDAQ:ZLAB

Biotechnology

Healthcare
$22.11 +3.42%

+$0.61 today

Market cap
$2.49B
Beta
0.78
P/E (TTM)
-11.4
EPS (TTM)
-$0.16
52W Low $15.96High $41.20

Volume 1.04M

Average 0.87M

ZLAB Weighted Avg Shares

Average number of basic shares outstanding during the period, used to calculate basic EPS.

Zai Lab LimitedNASDAQ: ZLAB

Weighted Avg Shares · Q2 FY2026 · quarter ended Jun 2026

Weighted avg shares grows, but more slowly than its trailing trend

Q2 FY2026 weighted avg shares of 111.7M shares rose 2.3% year over year, behind the +34.8% change in trailing-twelve-month weighted avg shares. Sequentially, it rose 0.9% from the prior quarter. Over 3 fiscal years it compounded at +125.3% a year.

Context

  • Weighted avg shares increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth recovers from +2.3% toward the trailing-twelve-month pace of +34.8%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterJun 2026
111.7M+0.9% QoQ
Last fiscal yearDec 2025
109.53M+10.7% YoY
LTMJun 2026
110.81M+34.8% YoY
Weighted Avg Shares past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+2.3%——
1 year+10.7%——
3-year CAGR+125.3%——
5-year CAGR——
10-year CAGR——

Weighted Avg Shares history

Shares · from the income statement

Latest · FY2025
109.53M USD
Year-over-year change
+10.7%
4-year CAGR
+85.3%

Weighted Avg Shares vs competitors

How ZLAB compares with its peers on the latest reported figures

  • ZLAB's LTM Jun 2026 weighted avg shares of 110.81M shares is the 2nd highest of the 4 companies compared; the peer median is 89.03M shares.
  • Its year-over-year change of +34.8% is the highest of 3, against a peer median of +19.3%.
  • Over three fiscal years its annual growth of +125.3% compares with a peer median of +7.9%.
ZLAB Competitors Peer median
Weighted Avg Shares for ZLAB and competitors
Company Period LTM YoY 3-year CAGR
HCMHUTCHMED (China) LimitedLTM Jun 2025206.7M +20.7%+0.4%
ZLABZai Lab LimitedLTM Jun 2026110.81M +34.8%+125.3%
AAPGAscentage Pharma Group InternationalFY202589.03M +17.9%+75.5%
ANLAdlai Nortye Ltd.LTM Jun 20247.76M —+7.9%
Peer median (excluding ZLAB) 89.03M+19.3%+7.9%

Competitors are the stored peer set for ZLAB. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue144.31M215.04M266.72M398.99M460.16M
Cost of Revenue52.24M74.02M95.82M147.86M191.08M
Gross Profit92.07M141.02M170.9M251.13M269.08M
Gross Margin63.8%65.6%64.1%62.9%58.5%
Research & Development573.31M286.41M265.87M234.5M220.9M
Selling, General & Admin218.83M258.97M281.61M298.74M277.61M
Operating Expenses792.14M545.38M537.48M533.25M492.65M
Depreciation & Amortization6.49M8.23M9.03M11.86M15.01M
EBITDA(689.46M)(434.84M)(365.11M)(242.99M)(158.25M)
EBITDA Margin-477.8%-202.2%-136.9%-60.9%-34.4%
Operating Income(700.06M)(404.36M)(366.57M)(282.12M)(223.57M)
Operating Margin-485.1%-188.0%-137.4%-70.7%-48.6%
Interest Income2.19M14.58M39.8M37.11M33.05M
Interest Expense0002.25M5.21M
Other Income / Expenses(3.35M)(38.93M)31.95M25.01M45.11M
Income Before Tax(703.41M)(443.29M)(334.62M)(257.1M)(178.46M)
Pre-Tax Margin-487.4%-206.1%-125.5%-64.4%-38.8%
Income Tax Expense1.06M000(2.93M)
Net Income(704.47M)(443.29M)(334.62M)(257.1M)(175.54M)
Net Margin-488.2%-206.1%-125.5%-64.4%-38.1%
EPS (Basic)(75.80)(46.30)(34.60)(2.60)(1.60)
EPS (Diluted)(75.80)(46.30)(34.60)(2.60)(1.60)
Weighted Avg Shares9.3M9.58M9.66M98.95M109.53M
Weighted Avg Shares (Diluted)9.3M9.58M9.66M98.95M109.53M

Zai Lab Limited

NASDAQ:ZLAB

Intrinsic Alpha fair value

Locked

Current Price

$22.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.